Announcement under Regulation 30 (LODR)-Dividend Updates
We refer to our letter dated 7th February 2018 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.00 a.m. and concluded at 3.15 p.m. The following items were considered and approved: Recommendation for payment of final dividend of Rs.53 per equity share of Rs 10 each for the year ended 31st December 2017.... Results - Financial Results For Dec 31, 2017
We refer to our letter dated 7th February 2018 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.00 a.m. and concluded at 3.15 p.m. The Board approved audited financial results for the year ended 31st December 2017. We enclose a copy of the Auditor's Report and audited financial results of the Company for the year ended 31st December 2017 approved at this Meeting and the as required... Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose herewith a copy of press release - "Sanofi launches new insulin ToujeoTM in India" contents of which are self-explanatory for your information and records. Sanofi launches new diabetes treatment insulin in India
Drug firm Sanofi India today said it has launched diabetes treatment Toujeo' insulin in the country. The product, which is a next generation basal insulin, is a once-daily long-acting basal anal Newspaper Publication
Dear Sirs Please find enclosed copies of the Notice of the Board Meeting of the Company published today, in newspapers, Business Standard and Sakal. Board to consider Final Dividend
Sanofi India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 22, 2018, inter alia, to:1. Approve the audited accounts for the year ended December 31, 2017.2. Recommend final dividend for the period mentioned above. Board Meeting On Feb 22, 2018
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on 22nd February 2018; inter alia to: Approve the audited accounts for the year ended 31st December 2017. Recommend final dividend for the period mentioned above Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A; boom
Sanofi is already one of Ablynx's big pharma partners, after striking a deal in July 2017 to find new treatments for inflammatory diseases How French drugmaker Sanofi's setback could lead to better dengue vaccines
Dengvaxia uses a widely effective yellow fever virus vaccine as its genetic backbone. To induce an immune response to dengue, certain yellow fever genes were swapped out for dengue genes